Hope4Cancer® Institute introduces Rigvir® Cancer Virotherapy as a brand new therapy.
Hope4Cancer® Institute is proud to announce its accreditation by the Latvian Virotherapy Center as a clinic authorized to treat patients with Rigvir® in Mexico. Download the free Rigvir E-book!
Virotherapy is emerging as a new wave in oncological treatments. Rigvir® is the world's first cancer virotherapy agent, the only one that is not genetically modified. Rigvir® has oncotropic and oncolytic ("seek" and "destroy") properties selectively against cancer cells. Once assimilated by the cancer cell, Rigvir® replicates in the cell which dies in the process. Healthy cells are not affected, resulting in no side effects and a high quality of life.
Rigvir® is an intensely studied live virus that has been shown to be non-replicative, i.e. it does not reproduce inside the human body nor does it transmit to others. While many pharmaceutical companies are working on the development of virotherapies, none of their engineered clinical candidates can boast of an effectiveness and safety profile anywhere close to that historically established for Rigvir®.
Rigvir® has passed all phases of clinical trials and is registered in Latvia as a prescription drug for the treatment of cancer. Rigvir® is an approved, state-sponsored medicine used by oncologists and sold in pharmacies in Latvia, and is also available through representatives in a few other countries. As a consequence of our accreditation by the Latvian Virotherapy Center, Rigvir® is now available as a standalone Hope4Cancer® treatment protocol.
Does Rigvir® Cancer Virotherapy Work Against All Cancers?
Initially developed as a powerful drug against melanoma, Rigvir is now approved as a medicine against numerous other cancers including the folllowing:
Rigvir® may also work against other cancers, but any other cancer types not on the list must be first evaluated by the medical team.
During his recent trip to Latvia, Dr. Antonio Jimenez, Medical Director of Hope4Cancer® Institute, completed an extensive training course on the use of virotherapy with Rigvir® in oncology and for the prevention of secondary immune deficiency. He also signed a Memorandum of Cooperation with the President and CEO of that Latvian Medical Export Association, Mr. Andrei Repisevski and the Managing Director of the Latvian Virotherapy Center, Ms. Gunta Kalnina, paving the way towards establishing cooperative efforts with Hope4Cancer® Institute to develop Rigvir® as a cancer treatment in different countries across the world.
Rigvir® is labelled as a "medicine" or "drug", does it classify as chemotherapy?
The answer is no. Hope4Cancer® Institute is cautious to introduce pharmaceutical products that could prove to be non-selective and toxic to its patients. While Rigvir® is a registered cancer medicine (drug) in Latvia, its ability to target cancer cells specifically and induce an immune response (also known as viral immunotherapy), completely safe clinical profile, high therapeutic index, and absence of side effects makes it unlike all available chemotherapy agents today.
On the same token, Rigvir® does not fall into the category of alternative and complementary medicine either, since it is a specific, defined pharmaceutical entity that has been established through a process of validated studies to qualify as a cancer drug. In other words, Rigvir® represents a totally new paradigm in cancer treatment, a new form of biologically targeted therapy, and adds to our portfolio of evidence-based cancer treatments.
"Interested in Rigvir®, who should I contact?"
Rigvir® therapy may not be for everybody. Find out if your condition qualifies for Rigvir® Cancer Virotherapy by contacting a Hope4Cancer® Institute Patient Coordinator through this website, and we will be happy to arrange for a free consultation between you and our Medical Director, Dr. Antonio Jimenez, to determine your eligibility for Rigvir® or other treatment options.